EarningsScore
SE · Healthcare / Medical Technology · Q3 2026 · 2026-10-30
Cellavision
"Management tone is moderately positive, led by a new CEO (Steve Ferguson) in his first full quarter. The report highlights strong Q3 results — 13.4% organic growth, EBITDA margin expansion to 32% — with confident language around Americas strength and BMA Application momentum."
Full analysis — hedging frequency, guidance certainty,
trend chart and 8-quarter history
Create free account →